01078nam a2200313 i 450099100087899970753620020507102703.0951121s1984 us ||| | eng 0671253026b10142502-39ule_instLE00638464ExLDip.to Fisicaita6(091)353.0087'22621.3.5TK9023.F67Ford, Daniel46872The cult of the atom :the secrete papers of the Atomic Energy Commission /Daniel Fordrev. and upd. ed.New York :Simon and Schuster,1984273 p. ;21 cm.Includes bibliographical references and index.Atomic power industry - United States.b1014250221-09-0627-06-02991000878999707536LE006 621.3.5 FOR12006000052405le006-E0.00-l- 00000.i1016942827-06-02Cult of the atom187047UNISALENTOle00601-01-95ma -engus 4105491nam 2200433 450 991083034030332120230715102714.01-119-76499-81-119-76497-1(MiAaPQ)EBC7261979(Au-PeEL)EBL7261979(OCoLC)1382695500(EXLCZ)992695937060004120230715d2023 uy 0engurcnu||||||||txtrdacontentcrdamediacrrdacarrierDrug compounding for veterinary professionals /Lauren R. Eichstadt Forsythe, Alexandria E. GochenauerHoboken, NJ :John Wiley & Sons, Inc.,[2023]©20231 online resource (174 pages)Print version: Eichstadt Forsythe, Lauren R. Drug Compounding for Veterinary Professionals Newark : John Wiley & Sons, Incorporated,c2023 9781119764960 Includes bibliographical references and index.Cover -- Title Page -- Copyright Page -- Contents -- Foreword -- Preface -- List of Acronyms -- About the Companion Website -- Introduction -- Chapter 1 Compounding Regulations -- Organizations and Regulatory Agencies Involved with Compounding -- Food and Drug Administration -- United States Pharmacopeia -- Drug Enforcement Administration -- State Boards of Pharmacy -- State Veterinary Boards -- Compliance Policy Guides and Guidance for Industry Documents -- What Is Compounding? -- The Food, Drug, and Cosmetic Act -- Animal Medicinal Drug Use Clarification Act -- Preparing Compounds from an Approved Product or a Pure Drug Powder -- Federal Versus State Law [8] -- Office Use Compounding -- Drug Quality and Security Act [26] -- Finding Additional Information -- References -- Chapter 2 Risk-Benefit Analysis of Compounded Medications -- Benefits of Compounded Products -- Dosage Form -- Flavoring -- Dosage Strength -- Eliminating Ingredients -- Availability Issues -- Appropriate Use of Compounded Medications -- FDA-Approved Drugs -- Compounded Medication Risks -- Compounded (USP) Versus Manufactured (cGMP) -- Risks Associated with Compounded Medications - A Look at the Literature -- Studies Showing Incorrect Potency -- Studies Showing Lack of Stability -- Studies Showing Lack of Efficacy -- Risks Associated with Specific Types of Compounds -- Active Ingredient Source Decisions -- Patient-Specific Compounding Versus Office Use Compounding -- Adverse Event Reporting -- Identifying Potential Formulation Issues -- Drugs Recalls -- Selecting a Compounding Pharmacy -- Client Education -- Reducing Risk in Practice -- Conclusion -- References -- Chapter 3 Beyond-Use Dating -- Factors Considered When Assigning BUDs and Expiration Dates -- USP Default BUDs -- Stability Studies -- Evaluating Stability Studies -- Determining BUDs for In-House Formulations.BUD Considerations When Prescribing Compounded Medications -- Conclusion -- References -- Chapter 4 Identifying High-Quality Compounding Pharmacies -- Case Study 1 -- Case Study 2 -- What to Evaluate -- General Practices -- Staff Skill Level -- Familiarity with Veterinary Medicine -- Pharmacy Culture -- Ways to Evaluate Compounding Pharmacies -- Looking Beyond the Pharmacy's Website -- What to Look for on a Tour -- Questions to Ask the Pharmacist in Charge -- Conclusion -- References -- Chapter 5 Formulation Development -- Dosage Forms -- Oral Administration -- Transdermal Administration -- Topical Administration -- Otic Administration -- Other Routes of Administration -- Ingredients -- Organic Salts -- Inorganic Salts -- Oral Liquid Medications -- Oral Solid Medications -- Emulsions -- Transdermal Medications -- Cream, Gel, and Ointment Medications -- Hazardous Drugs -- Beyond-Use Dates -- Formulation Resources -- Calculations -- Measurements Used in Compounding -- Displacement Factor -- Capsules: Packing Statistics -- Packing Statistic of Drug -- Average Weight of Ingredients -- Percentage of Drug per Capsule Using Bulk Powder -- Percentage of Drug per Capsule Using Manufactured Tablet -- Percentage/Amount of Filler per Capsule -- Conversion to Grams -- Compounding Formulations to Avoid -- Formulation Development Process -- Developing a Compounding Formula: Example 1 (USP Compounding Compendium) -- Developing a Compounding Formula: Example 2 (Stability-Indicating Assay) -- Compounding Formulation Assessment -- References -- Chapter 6 Compounding in House -- Documentation -- Master Formulation Record -- Compounding Record -- Formulation Record Components -- Quality Assurance and Quality Control -- Labeling -- Packaging and Storage -- Compounding Techniques -- Trituration -- Sifting -- Geometric Dilution -- Wetting -- Colored Tracers -- Equipment.Mortars and Pestles -- Glassware -- Containers -- Scales -- Spatulas and Measuring Devices -- Equipment Cleaning -- Training -- Formulation Instructions -- Species-Specific Information -- Flavoring -- Toxicities -- Potency Designations -- Feasibility for a Veterinary Clinic -- References -- Index -- EULA.Veterinary drugsVeterinary drugs.636.08951Eichstadt Forsythe Lauren R.1701024MiAaPQMiAaPQMiAaPQBOOK9910830340303321Drug compounding for veterinary professionals4084476UNINA03707nam 2200709Ia 450 991096333500332120230207224955.09780791479384079147938297814356064871435606485(CKB)1000000000479625(OCoLC)181102812(CaPaEBR)ebrary10575853(SSID)ssj0000118250(PQKBManifestationID)11146039(PQKBTitleCode)TC0000118250(PQKBWorkID)10052656(PQKB)10746935(MdBmJHUP)muse6589(Au-PeEL)EBL3407427(CaPaEBR)ebr10575853(OCoLC)923405117(DE-B1597)682771(DE-B1597)9780791479384(MiAaPQ)EBC3407427(Perlego)2673972(EXLCZ)99100000000047962520070117d2007 ub 0engurcn|||||||||txtccrCarnegie's model republic Triumphant democracy and the British-American relationship /A.S. EisenstadtAlbany State University of New York Pressc20071 online resource (222 p.) Bibliographic Level Mode of Issuance: Monograph9780791472231 079147223X Includes bibliographical references (p. 179-197) and index.Front Matter -- Contents -- Acknowledgments -- Introduction -- The Road to Triumphant Democracy -- Major Themes -- The Antithesis of Models -- Reconciling Ideals -- The British Critique -- Affirming America -- The Pan-Anglian Persuasion -- Conclusion -- Notes -- A Brief Note on Sources -- IndexAndrew Carnegie (1835–1919) has long been known as a leading American industrialist, a man of great wealth and great philanthropy. What is not as well known is that he was actively involved in Anglo-American politics and tried to promote a closer relationship between his native Britain and the United States. To that end, Carnegie published Triumphant Democracy in 1886, in which he proposed the American federal republic as a model for solving Britain's unsettling problems. On the basis of his own experience, Carnegie argued that America was a much-improved Britain and that the British monarchy could best overcome its social and political turbulence by following the democratic American model. He expressed a growing belief that the antagonism between the two nations should be supplanted by rapprochement. A. S. Eisenstadt offers an in-depth analysis of Triumphant Democracy, illustrating its importance and illuminating the larger current of British-American politics between the American Revolution and World War I and the fascinating exchange about the virtues and defects of the two nations.National characteristics, AmericanNational characteristics, BritishGreat BritainCivilizationGreat BritainRelationsUnited StatesUnited StatesEconomic conditions1865-1918United StatesPolitics and government1865-1900United StatesRelationsGreat BritainUnited StatesSocial life and customs1865-1918National characteristics, American.National characteristics, British.973.5Eisenstadt Abraham Seldin1920-1809224MiAaPQMiAaPQMiAaPQBOOK9910963335003321Carnegie's model republic4359908UNINA